Tennessee Oncology, PLLC   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Nashville TN United States (1976)

Organization Overview

First Clinical Trial
2012
NCT01594398
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Tennessee Oncology | Tennessee Oncology, PLLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Esophageal Neoplasms (Phase 2)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 1)

Stomach Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 12
  • # of Trial APIs: 22